Related Experiment Video

Updated: Aug 29, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Hypomagnesemia associated with chemotherapy in patients treated for acute lymphoblastic leukemia: possible mechanisms

Chun-Yuan Guo1, Jacqueline M Halton, Ronald D Barr

  • 1Department of Pediatrics, McMaster University, Hamilton, Canada.

Oncology Reports
|December 5, 2003
PubMed

Insights

Children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy experienced reduced magnesium levels. This hypomagnesemia was linked to increased bone formation and recovery during treatment.

Area of Science:

  • Pediatric Oncology
  • Bone Metabolism
  • Mineral Metabolism

Background:

  • Acute lymphoblastic leukemia (ALL) treatment can impact bone health.
  • Children with ALL may exhibit altered mineral metabolism during therapy.

Purpose of the Study:

  • To investigate changes in bone mineral density (BMD) and mineral metabolism in children with ALL during chemotherapy.
  • To explore the relationship between BMD, bone formation markers, and magnesium levels.

Main Methods:

  • Longitudinal study measuring body weight, height, and lumbar spine BMD in 40 children with ALL at diagnosis and 6 months post-chemotherapy initiation.
  • Measurement of serum and urinary biochemical indices of mineral metabolism in children with ALL.
  • Comparison with 40 age- and sex-matched healthy controls.

Main Results:

  • A reduction in fractional magnesium excretion was observed during chemotherapy.
  • Serum osteocalcin (a marker of bone formation) was low at diagnosis and increased with treatment.
  • Lumbar spine BMD Z-scores improved and correlated with serum osteocalcin; serum magnesium changes correlated negatively with BMD changes.

Conclusions:

  • Chemotherapy for ALL is associated with significant changes in mineral metabolism, particularly magnesium.
  • Rapid bone formation during recovery may lead to hypomagnesemia in children treated for ALL.
  • Monitoring magnesium levels and bone health is crucial during pediatric ALL treatment.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...